Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
Giuliano Ramadori
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
Kirsten S Hall
JAMA Oncology, 2020
View PDFchevron_right
What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?
Janusz Limon
Medical Oncology, 2013
View PDFchevron_right
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
Ian Judson
European Journal of Cancer, 2005
View PDFchevron_right
Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose
Jenni Hislop
2012
View PDFchevron_right
Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland
Melania Brzozowska
Medical Science Monitor, 2019
View PDFchevron_right
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
Axel Le Cesne
The Lancet Oncology, 2010
View PDFchevron_right
Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach
Annie Guerin
Journal of Gastrointestinal Cancer, 2012
View PDFchevron_right
Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
Chun-nan Yeh
Oncotarget, 2015
View PDFchevron_right
Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials
Shreyaskumar Patel
European Journal of Cancer, 2008
View PDFchevron_right
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
Ségolène Bisot-locard
PLOS ONE, 2018
View PDFchevron_right
Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
Pancras CW Hogendoorn
Journal of Clinical Oncology, 2009
View PDFchevron_right
Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts
Sandra Silberman
European Journal of Cancer, 2002
View PDFchevron_right
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian...
Elena Fumagalli
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
Dennis Priebat
JAMA oncology, 2018
View PDFchevron_right
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate
Maria Debiec-Rychter
European Journal of Cancer, 2008
View PDFchevron_right
Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor
Silke Cameron
Case Reports in Oncology, 2011
View PDFchevron_right
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial
Kirsten S Hall
JAMA: The Journal of the American Medical Association, 2012
View PDFchevron_right
Long-term outcome of GIST patients treated with delayed imatinib therapy
Nermina Ibišević
European Journal of Cancer, 2017
View PDFchevron_right
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era
J. Bonenkamp
British Journal of Surgery
View PDFchevron_right
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
Ian Judson, Sandra Silberman
The Lancet, 2001
View PDFchevron_right
CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate
Matias Chacon, Enrique Roca
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005
View PDFchevron_right
Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up
long cao
Journal of cancer research and clinical oncology, 2017
View PDFchevron_right
Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
Mary Keohan
Annals of Surgical Oncology, 2012
View PDFchevron_right
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
Jan Andersson
British journal of cancer, 2003
View PDFchevron_right
Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132
Dian Wang
Annals of Surgical Oncology, 2012
View PDFchevron_right
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
Janusz Limon
BMC Cancer, 2012
View PDFchevron_right
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
Jeffrey Yap
Journal of Clinical …, 2012
View PDFchevron_right
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
Giuliano Ramadori
Cancer, 2014
View PDFchevron_right
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Giuseppe Badalamenti
Lancet, 2013
View PDFchevron_right